Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Cutaneous Metastases and Malignant Wounds of the Breast
Description
The symposium covered cutaneous metastases and malignant wounds associated with breast cancer, detailing their presentations, management, and the role of dermatologists in palliative care. It was noted that up to 24% of breast cancer patients may develop skin metastases, varying from asymptomatic lesions to extensive malignant wounds. Malignant wounds result from tumors infiltrating the skin, disrupting blood supply and inducing tissue necrosis, leading to common distressing symptoms such as odor, bleeding, and pain, which significantly affect patients' quality of life. Metronidazole has been demonstrated to effectively reduce wound odor, and its prophylactic use is now standard in practice. The discussion also addressed treatment protocols, emphasizing careful management of symptoms such as pain and bleeding with various topical therapies, dressings, and potential surgical interventions depending on the patient's condition. Furthermore, rare malignancies like Paget's disease, angiosarcoma, and breast implant-associated lymphoma were briefly discussed, underscoring the necessity for early diagnosis via biopsy. Overall, dermatologists have a pivotal role in managing these complex wounds and should closely collaborate with oncologists to optimize care for patients with breast cancer.
View moreConclusions
- Cutaneous involvement is the most common manifestation of breast malignancies, constituting a significant aspect of patient care in dermatology.
- Up to 24% of breast cancer patients may develop cutaneous metastases, which can vary widely in severity.
- Patients with malignant wounds experience physical and psychological distress, emphasizing the need for comprehensive symptom management.
- Malodor is the most distressing symptom associated with malignant wounds, and metronidazole is effective in significantly reducing it.
- Oral metronidazole maintenance therapy shows better outcomes in managing wound malodor compared to topical or intermittent use.
- Silver and honey-impregnated dressings are effective in reducing malodor in malignant fungating wounds.
- Treatment for malignant wounds should be carefully tailored, taking into consideration the patient’s overall health and performance status.
- Palliative radiation therapy is beneficial for managing symptoms related to malignant wounds and enhances health-related quality of life.
- Surgical options remain feasible for some patients with breast malignancies, dependent on their performance status and lesion characteristics.
- Biopsy is crucial when atypical lesions are suspected to rule out rarer breast malignancies such as Paget's disease, angiosarcomas, and lymphomas.
- Johnson C. Cutis. 2021 March;107(03):E29-E36.
- Adderley UJ, et al. Cochrane Database of Systematic Reviews 2014, Issue 5. #CD003948.
- Alexander S. J Wound Care. 2009 Aug; 18(8):325-9.
- Alexander S. J Wound Care. 2009 Sep;18(9):374-82.
- Lancet. 1984 Jun 2;1(8388):1232-3.
- Ashford R, Plant G, Maher J, Teare L. Double-blind trial of metronidazole in malodorous ulcerating tumours.
- Eur J Cancer. 1992;28A(4-5):888-9.
- George R et al. BMJ Support Palliat Care 2017;7(3):286-291.
- Spratt DE et al. Efficacy of Skin-Directed Therapy for Cutaneous Metastases From Advanced Cancer: A Meta-Analysis. J Clin Oncol. 2014 Oct 1;32(28):3144-55.
- Reingold RE and Markova A et al. Quality of Life Before and After Treatment of Cutaneous Metastases with Palliative Radiotherapy. J Am Acad Dermatol. 2021 Nov 23:S0190-9622(21)02893-0.
- Markarian S, Holmes DR. Cancers (Basel). 2022;14(10):2422.
- Brenn T, et al. Histopathology. 2006;48(1):106-14.
- Flucke U, et al. Adv Anat Pathol. 2013;20(6):407-15.
- Fraga-Guedes C, et al. Breast Cancer Res Treat. 2015;151(1):131-40.
- Weaver J, et al. Semin Diagn Pathol. 2009;26(3):141-9.